ARCT

Arcturus Therapeutics (ARCT) P/E Ratio
P/E Ratio as of Oct 30, 2026: -3.33
Average-3.59
Median-3.63
Minimum-4.42
Maximum-2.97
-3.33
0.80 (19.37%)past month
The P/E ratio for Arcturus Therapeutics (ARCT) is -3.33 as of Oct 30, 2026. This represents a increase of 2.46% compared to its 12-month average P/E ratio of -3.25. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Arcturus Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Arcturus Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Arcturus Therapeutics to industry peers.
Arcturus Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Arcturus Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Arcturus Therapeutics to industry peers.
Arcturus Therapeutics (ARCT) P/E Ratio Insights
See Arcturus Therapeutics’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Arcturus Therapeutics (ARCT)
Order type
Buy in
Order amount
Est. shares
0 shares
Arcturus Therapeutics (ARCT) P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Oct 1, 2026 | $13.21 | -3.99 |
| Sep 1, 2026 | $16.225 | -4.90 |
| Aug 3, 2026 | $6.00 | -2.13 |
| Jul 1, 2026 | $6.89 | -2.45 |
| Jun 1, 2026 | $7.77 | -2.76 |
| May 1, 2026 | $8.63 | -3.62 |
| Apr 1, 2026 | $7.85 | -3.29 |
| Mar 2, 2026 | $8.35 | -3.50 |
| Feb 2, 2026 | $7.37 | -2.99 |
| Jan 2, 2026 | $6.25 | -2.54 |
Arcturus Therapeutics (ARCT) End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2026 | -3.33 | +33.73% |
| 2025 | -2.49 | -67.54% |
| 2024 | -7.67 | -187.96% |
| 2023 | 8.72 | -385.90% |
| 2022 | -3.05 | -36.19% |
| 2021 | -4.78 | — |
FAQs About Arcturus Therapeutics (ARCT) P/E ratio
The latest P/E ratio of Arcturus Therapeutics (ARCT) is -3.33, as of Oct 30, 2026. This is calculated based on its current stock price and earnings per share (EPS).
Arcturus Therapeutics’s last 12-month average P/E ratio is -3.25, compared to its current P/E ratio of -3.33. This reflects a increase of 2.46%.
Arcturus Therapeutics’s current P/E ratio of -3.33 is higher than its last 12-month average P/E of -3.25. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Arcturus Therapeutics’s average P/E ratio over the last 3 years is -7.51. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Arcturus Therapeutics’s average P/E ratio over the last 5 years is -1.65. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.
Arcturus Therapeutics (ARCT) P/E Ratio Insights
See Arcturus Therapeutics’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Arcturus Therapeutics (ARCT)
Order type
Buy in
Order amount
Est. shares
0 shares
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.